Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Long-Term Ataluren Study in Previously Treated Patients With Nonsense Mutation Dystrophinopathy
2011-004853-18Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Safety profile. Started Jan 2012; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2011-004853-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004853-18.